Preeclamptic Postpartum Antihypertensive Treatment

• Status: Recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: Female

Summary

The goal of this study is to compare whether antihypertensive treatment in the postpartum period decreases postpartum hypertension and its associated maternal morbidity, including risk of readmission and healthcare utilization in comparison with no treatment. Women with preeclampsia diagnosed during the antepartum, intrapartum or postpartum period will be randomized to either initiate antihypertensive treatment or standard of care. We hypothesize that postpartum antihypertensive treatment of patients with preeclampsia will decrease risk of hospital readmission, healthcare utilization and the number of severe range blood pressures at postpartum follow-up visits.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical College of Wisconsin
• Treatments: Antihypertensive Agents; Hydralazine; Labetalol; Nifedipine

Criteria

Inclusion Criteria:

• Age >= 18 years old

• Immediately postpartum (delivered in previous 96 hours)

• Diagnosed with preeclampsia during pregnancy, labor or immediately postpartum

• >50% of blood pressures in the postpartum period were elevated (systolic 140 or higher OR diastolic 90 or higher)

Exclusion Criteria:

• Chronic hypertension with superimposed preeclampsia

• Diagnosis of preeclampsia after discharge from delivery hospitalization

• Persistent severe range blood pressures after delivery requiring initiation of antihypertensive regimen by the care team

• >50% of blood pressures in the postpartum period were normal (systolic less than 140 AND diastolic less than 90)